Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced its intention to create two wholly owned subsidiaries to hold specific intellectual property. The first subsidiary will hold IP related to the improved processing and combustion-free delivery of nicotine and nicotine analogs, while the second subsidiary will hold IP related to the delivery of non-steroidal anti-inflammatory drugs, phosphodiesterase inhibitors and other active pharmaceutical ingredients. Per the update, this proposed structure, which is subject to ongoing legal and tax analysis, more suitably reflects the distinct customer bases and business applications for each subsidiary, allowing the company to focus its future research and consider financing structures and industry partnerships specifically optimized to each. Notably, Lexaria expects that its patented DehydraTECH™ technology will be utilized by both subsidiaries.
To view the full press release, visit http://cnw.fm/aj9HJ
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. develops and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the U.S. and Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com
More from CannabisNewsBreaks
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.cannabisnewswire.com